An interventional study of Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes. in Colo-rectal Cancer, sponsored by Yunnan Cancer Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Yunnan Cancer Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.
Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 55th largest by planned enrollment of the 163 interventional ones that give a count, is one of 18 that started in 2025, is one of 50 with no phase, reaches primary completion later than 61 of the 116 other live ones, and was the 201st registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18–80
Fudan University · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 18–75
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
211 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 69 · Phase 3 33 · Phase 4 4
First in 2004; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 110 across the 163 interventional studies, 400 across the 47 observational. Of the 37 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 211 have an industry lead sponsor. The 10 most frequent:
Yunnan Cancer Hospital is the lead sponsor of 30 studies on the registry; 26 are open to participants now.
Yunnan Cancer Hospital has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Colonic Neoplasms with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05709249Phase 3Jiangsu Famous Medical Technology Co., Ltd.Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer | 2027-04-01 |
| NCT07462143Phase 3RemeGen Co., Ltd.A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | 2027-05-12 |
| NCT06709144Phase 3Haixing Ju, MDBorderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer | 2027-06-30 |
| NCT07132008Phase 3First Affiliated Hospital of Guangxi Medical UniversityNeoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer | 2027-09-30 |
| NCT07565831Yunnan Cancer HospitalStudy on the Prediction of Regional Lymph Node Metastasis in Colorectal Cancer by Spectral CT Combined With MSI | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 211 studies in Colonic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospectively collect medical images and clinical data related to colorectal cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accuratestaging of colorectal cancer. Patientsdiagnosed with colorectal cancer in Yunnan Provincial Cancer Hospital from August 2025 to December 2026 were consecutively included,and after scanning with Philips Quark CT, the TNM stage of colorectal cancer patients was assessed by two radiologists, and finally statistical analysis was performed
Diagnostic Test: Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes.
The CT scan is part of the standard treatment protocol.
Pathological TNM staging
Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Time frame: 1 day
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 16 months is below that.
Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunnan Cancer Hospital